<DOC>
	<DOC>NCT00151788</DOC>
	<brief_summary>The effects of pactimibe versus placebo on the progression of atherosclerosis in the carotid arteries will be assessed using standard ultrasound techniques.</brief_summary>
	<brief_title>Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Carotid Artery Diseases</mesh_term>
	<criteria>Confirmed diagnosis of heterozygous familial hypercholesterolemia Ambulatory male (40 to 75 years, inclusive) or female (45 to 75 years, inclusive) subjects Calculated LDLC level greater than or equal to 100 mg/dL (or 2.5 mmol/L) and triglycerides less than 500 mg/dL (5.65 mmol/L) while on usual and stable lipidlowering therapy Breast feeding or lactating women Previous organ transplantation Highgrade stenosis (&gt;75%) or the occlusion of any segment of either carotid artery History of carotid endarterectomy, or insertion of carotid artery stent or are scheduled to have either of these procedures</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>